The treatment of chronic myeloid leukemia, data from Gujarat Cancer and Research Institute, Ahmedabad
Gujarat Cancer and Research Institute, Ahmedabad presented data of total 840 patients, out of which 775 (90%) were in chronic phase. Complete hematological response (CHR) was seen in 96% of patients and median time to achieve (CHR) was 2 months. Complete cytogenetic response was seen in 36%.
Saved in:
| Main Author: | Sandip A Shah |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Thieme Medical and Scientific Publishers Pvt. Ltd.
2013-01-01
|
| Series: | Indian Journal of Medical and Paediatric Oncology |
| Subjects: | |
| Online Access: | http://www.ijmpo.org/article.asp?issn=0971-5851;year=2013;volume=34;issue=3;spage=189;epage=192;aulast=Shah |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Report of patients with chronic myeloid leukemia, from hematology clinic, Ahmedabad, Gujarat 2000-2010 at 1 st myelostone meeting: Indian evidence of chronic myelogenous leukemia
by: Uday R Deotare, et al.
Published: (2013-01-01) -
Report of chronic myeloid leukemia from All India Institute of Medical Sciences, 1990-2010
by: Pravas Mishra, et al.
Published: (2013-01-01) -
Report of chronic myeloid leukemia in chronic phase from Dr. Senthil Rajappa, 2002-2009
by: Senthil Rajappa, et al.
Published: (2013-01-01) -
Chronic myeloid leukemia treatment with Imatinib: An experience from a private tertiary care hospital
by: D C Doval, et al.
Published: (2013-01-01) -
Long-term treatment outcome in chronic myeloid leukemia patients in accelerated phase treated with imatinib (glevec®)
by: L. A. Antipova, et al.
Published: (2022-11-01)